Natixis Advisors LLC Has $27.61 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

Natixis Advisors LLC grew its holdings in Hologic, Inc. (NASDAQ:HOLX) by 10.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 338,924 shares of the medical equipment provider’s stock after purchasing an additional 31,436 shares during the period. Natixis Advisors LLC owned about 0.15% of Hologic worth $27,609,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Coastline Trust Co acquired a new position in shares of Hologic in the 3rd quarter valued at about $118,000. Empowered Funds LLC increased its holdings in shares of Hologic by 8.8% in the 3rd quarter. Empowered Funds LLC now owns 3,603 shares of the medical equipment provider’s stock valued at $294,000 after purchasing an additional 291 shares during the period. Empirical Finance LLC increased its holdings in shares of Hologic by 1.8% in the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock valued at $690,000 after purchasing an additional 147 shares during the period. CIBC Asset Management Inc increased its holdings in shares of Hologic by 7.9% in the 3rd quarter. CIBC Asset Management Inc now owns 33,973 shares of the medical equipment provider’s stock valued at $2,767,000 after purchasing an additional 2,483 shares during the period. Finally, OneDigital Investment Advisors LLC grew its stake in shares of Hologic by 5.4% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 7,075 shares of the medical equipment provider’s stock valued at $576,000 after buying an additional 360 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Up 0.2 %

HOLX opened at $78.79 on Tuesday. Hologic, Inc. has a 1-year low of $67.59 and a 1-year high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $18.30 billion, a price-to-earnings ratio of 23.66, a P/E/G ratio of 2.48 and a beta of 0.98. The business has a 50 day moving average of $80.63 and a 200-day moving average of $78.28.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same period in the prior year, the business earned $0.89 earnings per share. Hologic’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Raymond James boosted their price target on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, October 15th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. UBS Group boosted their price target on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, Leerink Partners decreased their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Hologic currently has an average rating of “Moderate Buy” and an average price target of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.